Isbn: 9781841845791 - angiotensin ii receptor antagonists: current perspectives (3 Ergebnisse)

- Hardcover
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USARomtrade Corp.
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 121,43
Versand gratisVersand innerhalb von USAAnzahl: 1 verfügbar
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

- Hardcover
Anbieter: moluna, Greven, Deutschlandmoluna
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 180,16
EUR 48,99 VersandVersand von Deutschland nach USAAnzahl: Mehr als 20 verfügbar
Zustand: New. Mancia GiuseppeSince angiotensin II is one of the most potent vasoconstrictors and an important stimulus for the secretion of aldosterone from the adrenal gland, the development of of angiotensin II inhibitors is an important step in regulating blood.

Angiotensin II Receptor Antagonists : Current Perspectives
Mancia (Department of Clinical Medicine and Prevention Giuseppe
- Hardcover
Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH
Verkäufer/-in kontaktierenVerkäufer/-in mit 5 SternenZustand: Neu
EUR 229,70
EUR 30,50 VersandVersand von Deutschland nach USAAnzahl: 2 verfügbar
Buch. Zustand: Neu. Neuware - Since angiotensin II is one of the most potent vasoconstrictors and an important stimulus for the secretion of aldosterone from the adrenal gland, the development of of angiotensin II inhibitors is an important step in regulating blood pressure. This class of drug is well-tolerated by pateints and these drugs have the added advantage over ACE inhibitors in that they are not associated with cough. Because most drugs can be given once daily and, like ACEIs, they have a useful additive hypotensive effect in combination with diuretics, they are a welcome therapeutic tool in the treatment of hypertension. This Second Edition builds on the success of the first and brings to the reader all the latest developments, clinical trial data, and the contributors's personal perspectives when treating patients with angiotensin II receptors antagonists.…